علاج قصور القلب المتقدم مع انخفاض الكسر القذفي المقاوم للعلاج الطبي الموجَّه بالإرشادات

References

DOI: 10.1161/CIR.0000000000001063

In patients with advanced (stage D) HF refractory to GDMT and device therapy who are eligible for and awaiting MCS or cardiac transplantation, continuous intravenous inotropic support is reasonable as "bridge therapy."

In select patients with advanced HFrEF with NYHA class IV symptoms who are deemed to be dependent on continuous intravenous inotropes or temporary MCS, durable LVAD implantation is effective to improve functional status, QOL, and survival.

For selected patients with advanced HF despite GDMT, cardiac transplantation is indicated to improve survival and QOL.